These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32751752)

  • 1. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II.
    Wang J; Bhalla A; Ullman JC; Fang M; Ravi R; Arguello A; Thomsen E; Tsogtbaatar B; Guo JL; Skuja LL; Dugas JC; Davis SS; Poda SB; Gunasekaran K; Costanzo S; Sweeney ZK; Henry AG; Harris JM; Henne KR; Astarita G
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
    J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
    Zhang H; Wood T; Young SP; Millington DS
    Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
    Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK
    J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening and diagnosis of mucopolysaccharidoses.
    Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
    Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS.
    Menkovic I; Lavoie P; Boutin M; Auray-Blais C
    Bioanalysis; 2019 Apr; 11(8):727-740. PubMed ID: 30994022
    [No Abstract]   [Full Text] [Related]  

  • 11. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
    Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
    Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
    Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel LC-MS/MS assay to quantify dermatan sulfate in cerebrospinal fluid as a biomarker for mucopolysaccharidosis II.
    Pan P; Chen M; Zhang Z; Corte AD; Souza C; Giugliani R; Pan L; Qiu Y; Amaravadi L; Wu J
    Bioanalysis; 2018 Jun; 10(11):825-838. PubMed ID: 29863901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
    Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
    Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
    Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Glycosaminoglycans in Urine by Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry.
    Zhang H; Young SP; Millington DS
    Curr Protoc; 2023 Mar; 3(3):e701. PubMed ID: 36929617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.